Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) EBITDA Margin (2020 - 2026)

Treace Medical Concepts filings provide 6 years of EBITDA Margin readings, the most recent being 15.04% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 1418.0% to 15.04% in Q4 2025 year-over-year; TTM through Dec 2025 was 27.75%, a 110.0% decrease, with the full-year FY2025 number at 27.75%, down 110.0% from a year prior.
  • EBITDA Margin hit 15.04% in Q4 2025 for Treace Medical Concepts, up from 32.37% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 0.87% in Q4 2024 to a low of 57.51% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 30.74% (2022), compared with a mean of 27.55%.
  • Biggest five-year swings in EBITDA Margin: plummeted -3790bps in 2022 and later surged 2787bps in 2023.
  • Treace Medical Concepts' EBITDA Margin stood at 16.74% in 2021, then soared by 47bps to 8.92% in 2022, then dropped by -8bps to 9.6% in 2023, then soared by 91bps to 0.87% in 2024, then plummeted by -1637bps to 15.04% in 2025.
  • The last three reported values for EBITDA Margin were 15.04% (Q4 2025), 32.37% (Q3 2025), and 36.73% (Q2 2025) per Business Quant data.